Latest news with #Funderburk
Yahoo
28-05-2025
- Business
- Yahoo
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 12:50 p.m. EDT. A webcast of the fireside chat will be accessible via the 'Events & Presentations' section of Monte Rosa's website at and an archived version will be made available for 30 days following the presentation. About Monte RosaMonte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa's QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry's leading pipeline of MGDs, which spans autoimmune and inflammatory diseases, oncology, and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit InvestorsAndrew Funderburk ir@ MediaCory Tromblee, Scient PRmedia@
Yahoo
02-05-2025
- Yahoo
Georgia man faces felony domestic battery charges in Bay County
BAY COUNTY, Fla. (WMBB) – A Georgia man has been charged with multiple counts of Felony Domestic Battery after he allegedly hit, choked, and used a wrench to strike his fiancée. According to a news release, the Bay County Sheriff's Office responded to the Aqua View Motel on Friday morning regarding a battery on a female. The victim was visibly distressed, bloody, and bruised on her face, officials wrote. The victim said she was in a verbal argument with her fiancé, 44-year-old Robert Funderburk, and that is when he became increasingly aggressive and hit her in the face with a closed fist. Walton County man found guilty on DUI manslaughter charge Authorities said the marks on the victim's neck were consistent with being forcibly grabbed and that other factors led them to believe that there was a loss of oxygen to the brain from her being choked. An arrest warrant was quickly obtained after Funderburk refused to leave his room at their Airbnb on 6215 Thomas Drive. Verbal contact was made, and he peacefully gave himself up without incident. Authorities confirmed that inside the room, a bloody wrench was found and is believed to have been used to strike the victim. They also discovered a towel covered in blood. Funderburk is an active member of the Outlaws Motorcycle Club and is visiting from Georgia. He was booked into the Bay County Jail, and his bond hearing is set for Saturday. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
24-02-2025
- Business
- Yahoo
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 2:30 p.m. EST. A webcast of the presentation will be accessible via the 'Events & Presentations' section of Monte Rosa's website at and an archived version will be made available for 30 days following the presentation. About Monte RosaMonte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa's QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry's leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit InvestorsAndrew Funderburk ir@ MediaCory Tromblee, Scient PRmedia@ in to access your portfolio
